Drug Profile

Breast cancer vaccine - Lumos Pharma

Alternative Names: breast-cancer-vaccine-NewLink-Genetics; HyperAcute - Breast cancer vaccine; HyperAcute-breast-cancer-vaccine

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NewLink Genetics Corporation
Class Cancer vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Breast cancer

Most Recent Events

18 Apr 2012 Discontinued - Phase-I/II for Breast cancer in USA (Intradermal)
06 Jul 2006 NewLink Genetics terminates phase I/II trial in Breast cancer in the USA (NCT00090480)
23 Jun 2005 Phase-I/II clinical trials in Breast cancer in USA (Intradermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com